Hester Biosciences Limited, one of the leading animal healthcare companies in Ahmedabad, India has announced its results for the financial year 2022. In the financial year 2022, the company has invested Rs. 39.48 crore as against a net profit of Rs. An increase of 14 per cent over net profit of Rs 34.70 crore.
In the financial year 2021, Rs. 214.33 crore in FY 2022 against the company’s 10% increase to Rs. 235.01 crore. EPS for FY 2022 is Rs. 46.41 crore in the previous financial year. Was 14 percent higher than the EPS of 34.70.
Consolidated operations have mainly seen the impact of Hester Nepal’s remarkable performance. Hester Nepal has shown a 193% increase in sales in FY2022. In the financial year 2021, Rs. 0.97 crore against a loss of Rs. 2.29 crore net profit.
The company hopes to see further growth in sales over the next year after the supply of PPR vaccine resumes under FAO tenders. Nepal’s domestic market is gearing up for the company’s live and inactivated vaccines.
Hester Africa has received regulatory approvals for the production of PPR and CBPP vaccines. Production of this vaccine has started and quality parameters are being followed. The effect of its sale will be seen in the financial year 2023. The project will help Hester become a leading company in Africa and will make a significant contribution to the economic and social development of the African continent in addition to increasing Hester’s sales and profits.
The company has received a national tender from the Animal Husbandry Department to supply 200 million doses to eradicate PPR from the entire country in a span of two years. The supply orders have been delayed and are expected to start in the first quarter of FY2023.